Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Novacyt  /  Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,780   0,000   (0,00%) Dagrange 0,670 - 0,791 540.429   Gem. (3M) 1,1M

Novacyt de volgende biotech raket!

Volgen
70.728 Posts
Pagina: «« 1 ... 2440 2441 2442 2443 2444 ... 3537 »» | Laatste | Omlaag ↓
  4. [verwijderd] 27 januari 2021 15:57
    www.ft.com/content/272a4903-4a0c-4736...

    Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at www.ft.com/tour.
    https://www.ft.com/content/272a4903-4a0c-4736-914a-ca5a4a51ba37

    One of the companies tasked by the UK government with creating a rapid coronavirus antibody test had “all outstanding orders” cancelled this month, a development it did not disclose to the market when it issued a trading update on Tuesday.

    Abingdon Health leads the UK Rapid Test Consortium formed by a group of manufacturers in response to the government’s request to develop a homegrown test to reliably measure who has previously been infected by coronavirus.

    The Yorkshire-based biotechnology group listed on London’s Aim in mid-December, raising £22m and telling investors that the contract with the Department for Health and Social Care was critical to its business.

    The contract was for an initial 1m tests, with the possibility of millions more orders worth up to £75m. The company said on Tuesday it had delivered the initial batch on January 8. Three days later, DHSC cancelled “all outstanding orders” for Abingdon’s test, according to a letter seen by the Financial Times, citing the company’s failure to win approval from the medicines regulator for home use of the test by a Christmas deadline.

    “Abingdon Health did not obtain?.?.?.?approval for home use of its antibody lateral flow test (“LFT”) devices by 25 December 2020,” the government said in the letter to non-profit legal advocacy group the Good Law Project. “As a consequence, on 11 January 2021 the secretary of state exercised his contractual right under the August contract to cancel with immediate effect all outstanding orders placed with Abingdon Health.” 

    The letter left open the possibility of the government buying Abingdon’s tests in future through its “dynamic purchasing system”, under which it buys from bidding companies on an ad hoc basis.

    The Good Law Project has been suing the government in judicial review proceedings to shed light on billions of pounds of contracts handed out by the UK government during the pandemic. It has challenged the way Abingdon’s was awarded, claiming the government did not sufficiently assess the accuracy of the tests and that there was not sufficient bidder competition. The government has denied the claims.

    The DHSC said that while it did not comment on ongoing legal proceedings, “we have always been clear that government contracts must deliver value for taxpayer money and we will take action in instances where this does not happen”.

    Abingdon said on Wednesday that as there had been no orders to cancel it had decided not to issue a statement to the market.

    “In consultation with advisers, the decision was made that there was not a statement to make as there were no outstanding orders with the DHSC and therefore no orders to be cancelled,” the company said in a statement to the Financial Times.

    It added: “Abingdon continues to manufacture the product for potential public and private sector use in the UK and internationally.”

    Abingdon’s December 11 prospectus said the government had not issued additional orders beyond the initial 1m but warned about the government’s termination rights in the event the company missed the Christmas approval deadline.

    “If the DHSC were to exercise such right, it could have a significant negative impact on the group’s results, overall financial condition and prospects,” the prospectus said. If no further orders were made, Abingdon’s board believed a similar volume could be sold to other buyers at the same or a higher price, according to the listing document.

    In Tuesday’s trading update Abingdon — whose shares are up 36 per cent since its float last month, valuing the business at £125m — said it expected revenues for the six months to the end of December to be in line with expectations at about £7.7m.
     
    “Regarding the current DHSC contract, as noted previously, this will expire on 14 February 2021 and, in line with the government’s shift to a dynamic purchasing strategy, the board expects that any future orders will be received via an application by the company to future DHSC tender notices,” the company said.

    Abingdon came under scrutiny last year after Public Health England researchers found its antibody test to be less accurate than the company’s 99 per cent claim. The group in November questioned the researchers’ methodology and said: “Our customer, DHSC, is satisfied with the performance of the test.”

    Daar gaat ODX door geraakt worden right?
  9. [verwijderd] 27 januari 2021 16:00
    quote:

    Galapapositief schreef op 27 januari 2021 15:57:

    www.ft.com/content/272a4903-4a0c-4736...

    One of the companies tasked by the UK government with creating a rapid coronavirus antibody test had “all outstanding orders” cancelled this month, a development it did not disclose to the market when it issued a trading update on Tuesday.

    Abingdon Health leads the UK Rapid Test Consortium formed by a group of manufacturers in response to the government’s request to develop a homegrown test to reliably measure who has previously been infected by coronavirus.

    ....

    Dit is echt zwaar positief voor Novacyt lijkt me. Er ontstaat weer meer ruimte en vraag voor Nova om aan te voldoen. Opschieten met die ontwikkelingen dus.
  10. snowhmr 27 januari 2021 16:00
    quote:

    Tommaco schreef op 27 januari 2021 15:55:

    [...]

    Waar heb je dat gelezen?
    Via het telegram app daar hebben ze ook de gehele verklaring dat de overheid na de order van 1 miljoen daarna nooit meer besteld heeft en niet gaat bestellen. ze gaan nu door met verkoop aan bedrijven en particulieren. Dit lijkt mij voor Nova juist positief. alleen wil mijn andere aandelen verkopen maar de giro werkt niet mee
70.728 Posts
Pagina: «« 1 ... 2440 2441 2442 2443 2444 ... 3537 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee